2022-12-28| M&ASpecial

GeneOnline’s Pick: Top 10 M&A Deals in 2022

by GeneOnline
Share To
2022 is an eventful year in terms of restructuring the global biomedical industry. Many major pharmaceutical companies are benefiting from the huge demand for pandemic prevention brought about by COVID-19, and have generated impressive revenues from vaccines, pharmaceuticals, and products related to testing equipment. This is why they continue to allocate funds to further R&D investments in 2022, or to reorganize their product lines through licensing, strategic alliances, and mergers and acquisitions.
Global biotech M&A market in 2022 experienced its slowest pace since 2018, with a downward trend in terms of both the number of deals and transaction amounts. According to statistics from PwC as of mid-November 2022, the number of deals in the pharmaceutical and life sciences sector in 2022 is 266, marking a 28% decrease compared to 2021, and the total deal value is $137 billion, registering a 49% reduction from the previous year. Nonetheless, this does not necessarily mean that the global biotech investment market is shrinking. The largest biotech M&A deal of the year comes at the end of 2022 - Amgen’s $27.8 billion acquisition of Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare autoimmune diseases.

It's free! Log in now to read

Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro
Targeted Cancer Therapy Breakthrough: Degrader-Antibody Conjugates (DACs) Advance to Clinical Trials
Degrader-Antibody Conjugates (DACs): Targeted Degradation for Therapeutics
Scroll to Top